"EAST" SEARCH HISTORY INCLUDING INTERFERENCE 10/800,328

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2450	514/217.07 OR 514/249 OR 540/599 OR 544/349	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/02/08 09:21
L2	647	L1 AND (ANTIPSYCHOTIC OR DOPAMINE OR SEROTONIN OR NOREPINEPHRINE OR EPINEPHRINE)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/02/08 09:22
L3	111	L2 AND (AZABICYCLO OR PYRIDOPYRAZINE OR PYRAZINOPYRIDINE OR ISOXAZOLE OR BENZOISOXAZOLE)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/02/08 09:22
L4	1	L3 AND PYRIDYLOXYMETHYL	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/02/08 09:23
L5	82	L3 AND (ANTAGONIST OR ANTAGONISTS)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/02/08 09:23
L6	81	L5 NOT L4	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/02/08 09:23

STN SEARCH TRANSCRIPT 10/800,328

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  DEC 05  CASREACT(R) - Over 10 million reactions available
 NEWS  4  DEC 14  2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS  5  DEC 14  2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS  6  DEC 14  CA/CAplus to be enhanced with updated IPC codes
 NEWS  7  DEC 21  IPC search and display fields enhanced in CA/CAplus with the
                  IPC reform
 NEWS  8  DEC 23  New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                  USPAT2
 NEWS  9  JAN 13  IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS 10  JAN 13  New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                  INPADOC
 NEWS 11  JAN 17  Pre-1988 INPI data added to MARPAT
 NEWS 12  JAN 17  IPC 8 in the WPI family of databases including WPIFV
 NEWS 13  JAN 30  Saved answer limit increased
 NEWS 14  JAN 31  Monthly current-awareness alert (SDI) frequency
                  added to TULSA

 NEWS EXPRESS  JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:04:49 ON 08 FEB 2006

=> FILE REG
COST IN U.S. DOLLARS                              SINCE FILE     TOTAL
                                                       ENTRY   SESSION
FULL ESTIMATED COST                                     0.21      0.21

FILE 'REGISTRY' ENTERED AT 10:04:57 ON 08 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 FEB 2006  HIGHEST RN 873652-66-5
DICTIONARY FILE UPDATES:   6 FEB 2006  HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*******************************************************************
*                                                                 *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,  *
* effective March 20, 2005.  A new display format, IDERL, is now   *
* available and contains the CA role and document type information. *
*                                                                 *
*******************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\Stnexp\Queries\BRIGHT ANTIPSYCHOTICS.str
```



chain nodes :
21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 24 25 26 27
28 29
chain bonds :
6-11 21-22 21-24
ring bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-10 5-6 7-8 8-9 9-10 11-12 11-15 12-13 12-16
13-14 13-19 14-15 16-17 17-18 18-19 24-25 24-29 25-26 26-27 27-28 28-29

exact/norm bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-10 5-6 6-11 7-8 8-9 9-10 11-12 11-15 13-14
14-15 21-22 21-24 24-25 24-29 25-26 26-27 27-28 28-29
normalized bonds :
12-13 12-16 13-19 16-17 17-18 18-19
isolated ring systems :
containing 1 : 11 : 24 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
21:CLASS 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> D L1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 10:05:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 44 TO 476

L3 13 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 10:05:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 171 TO ITERATE

100.0% PROCESSED 171 ITERATIONS 168 ANSWERS
SEARCH TIME: 00.00.01

L4 168 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY 166.94 TOTAL SESSION 167.15

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:05:26 ON 08 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 8 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 7 Feb 2006 (20060207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L4
L5 3 L4

=> D 1-3 IBIB ABS

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:698356 CAPLUS
DOCUMENT NUMBER: 143:179645
TITLE: Compositions containing atypical antipsychotics and azabicyclic compounds for treating CNS disorders
INVENTOR(S): Brodney, Michael A.; Howard, Harry R.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005171086	A1	20050804	US 2005-48013	20050128
WO 2005082370	A1	20050909	WO 2005-IB106	20050117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-539939P P 20040129
OTHER SOURCE(S): MARPAT 143:179645
AB Disclosed is an aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound, a pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression. For example, capsules for Parkinson's disease contained ziprasidone hydrochloride 200, benzisoxazole substituted azabicyclic compd 20, Methocel E3 222, lactose monohydrate 222, Aerosil 10, SLS 10 mg.

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:780698 CAPLUS
DOCUMENT NUMBER: 141:296048
TITLE: A preparation of pyrido[1,2-a]pyrazine derivatives, useful for the treatment of schizophrenia and depression
INVENTOR(S): Bright, Gene Michael; Brodney, Michael Aaron; Wlodecki, Bishop
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

APPLICANTS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081007	A1	20040923	WO 2004-IB499	20040223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2518740	AA	20040923	CA 2004-2518740	20040223
EP 1608648	A1	20051228	EP 2004-713592	20040223

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

NL 1025710	A1	20040914	NL 2004-1025710	20040312
NL 1025710	C2	20051010		
US 2005026922	A1	20050203	US 2004-800320	20040312
NO 2005004095	A	20050926	NO 2005-4095	20050902

PRIORITY APPLN. INFO.: US 2003-453925P P 20030312
WO 2004-IB499 W 20040223

OTHER SOURCE(S): MARPAT 141:296048
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of pyrido[1,2-a]pyrazine derivs. of formula I [wherein: X is O, NH, or N(alkyl); Y is (CH2)0-1; Z is CHO, C(O)-alkoxy, SO2-alkoxy, Me, CH2OH, etc.; R1 and R2 are independently selected from H, halogen, (cyclo)alkyl, or alkoxy, etc.], useful for treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression. Thus, e.g., II was prepared via reaction of morpholine with (7R,9aS)-trans-methanesulfonic acid 6-(2-benzo[d]isoxazol-3-yl-octahydropyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl ester (preparation given). The prepared compds. were determined to be antagonists and/or inverse agonists of human D2, human 5-HT1B, and human 5-HT2A receptors. For instance, preferred compound II exhibited Ki value of about 20 nM or less for at least two of the following receptors: D2, 5-HT1B, and 5-HT2A.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:672814 CAPLUS
DOCUMENT NUMBER: 131:299376
TITLE: Azabicyclic 5-HT1 receptor ligands, particularly 2-(benzo[d]isoxazol-3-yl)-7-(phenoxymethyl)octahydropyrido[1,2-a]pyrazine derivatives
INVENTOR(S): Bright, Gene Michael
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9952907	A1	19991021	WO 1999-IB457	19990318

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2327782	AA	19991021	CA 1999-2327782	19990318
AU 9932687	A1	19991101	AU 1999-32687	19990318
AU 749254	B2	20020620		
BR 9909522	A	20001219	BR 1999-9522	19990318
TR 200002932	T2	20010122	TR 2000-200002932	19990318
EP 1070065	A1	20010124	EP 1999-945686	19990318
EP 1070065	B1	20030903		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO

JP 2002511469	T2	20020416	JP 2000-543464	19990318
JP 3496759	B2	20040216		
NZ 507010	A	20030530	NZ 1999-507010	19990318
CN 1117092	B	20030806	CN 1999-807195	19990318
AT 248838	E	20030915	AT 1999-945686	19990318
PT 1070065	T	20031231	PT 1999-945686	19990318
ES 2204154	T3	20040416	ES 1999-945686	19990318
TW 555758	B	20031001	TW 1999-88105301	19990402
ZA 9902596	A	20001008	ZA 1999-2596	19990408
US 6525048	B1	20030225	US 2000-403892	20000118
NO 2000005004	A	20001127	NO 2000-5004	20001004
HR 2000000653	A1	20010430	HR 2000-653	20001004
BG 104915	A	20010731	BG 2000-104915	20001107
HK 1035719	A1	20031224	HK 2001-106215	20010904
US 2003181458	A1	20030925	US 2003-364804	20030211
US 6887905	B2	20050503		

PRIORITY APPLN. INFO.:	US 1998-81237P	P	19980409
	WO 1999-IB457	W	19990318
	US 2000-403892	A3	20000118

OTHER SOURCE(S): MARPAT 131:299376
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. I [wherein R3, R4, Z = H, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)alkoxy(fluoro)alkyl; W = alkoxymethyl, (di)(alkyl)aminomethyl, or CH2NR1R2 where R1R2 = atoms to complete a heterocycle such as pyrrolidine; with provisos]. The compds. are agonists or antagonists of serotonin 1A receptors, and/or antagonists of serotonin 1D receptors, and are thus useful as psychotherapeutic agents. These compds. may be co-administered with 5-HT reuptake inhibitors, and are potentially useful for treating a wide variety of conditions. Approx. 40 synthetic examples are given. For instance, title compound II was prepared in 5 steps: (1) Mitsunobu etherification of starting material (7R,9aS)-trans-III with Me 3-hydroxybenzoate (75%); (2) reduction of the Me ester to an alc. using LiAlH4 (100%); (3) mesylation of the alc. and reaction of the mesylate with pyrrolidine (56%); (4) removal of the BOC protecting group (100%); and coupling with 3-chloro-5-fluorobenzo[d]isoxazole (36%). In assays against 5-HT receptors in vitro, all tested compds. I exhibited IC50 values of < 0.60 mM for 5-HT1D receptors, and < 1.0 mM for 5-HT1A receptors.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D 3 HITSTR

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
IT **247091-72-1P 247091-73-2P 247091-74-3P**
247091-75-4P 247091-76-5P 247091-77-6P
247091-78-7P 247091-79-8P 247091-80-1P
247091-81-2P 247091-82-3P 247091-83-4P
247091-84-5P 247091-85-6P 247091-88-9P
247091-89-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzisoxazolyloctahydropyridopyrazine derivs. as 5-HT1 receptor ligands)

NO PYRIDYLOXY.METHY GROUP IN ANY OF THESE COMPOUNDS

RN 247091-72-1 CAPLUS
CN Benzenemethanol, 3-[[(7R,9aS)-2-(5-fluoro-1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-73-2 CAPLUS
CN Benzoic acid, 3-[[(7R,9aS)-2-(5-fluoro-1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-74-3 CAPLUS
CN Benzenemethanol, 3-[[(7R,9aS)-2-(5-fluoro-1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-75-4 CAPLUS
CN Benzoic acid, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-76-5 CAPLUS
CN Benzenemethanol, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-77-6 CAPLUS
CN Benzoic acid, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-78-7 CAPLUS
CN Benzenemethanol, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-79-8 CAPLUS
CN Benzoic acid, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-80-1 CAPLUS
CN Benzenemethanol, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-5-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-81-2 CAPLUS
CN Benzoic acid, 5-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-2-chloro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-82-3 CAPLUS
CN Benzenemethanol, 5-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-83-4 CAPLUS
CN Benzoic acid, 4-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-84-5 CAPLUS
CN Benzenemethanol, 4-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-85-6 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)-7-[[4-(chloromethyl)phenoxy]methyl]octahydro-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-88-9 CAPLUS
CN Benzonitrile, 4-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-89-0 CAPLUS
CN Benzenemethanamine, 4-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **247091-25-4P 247091-26-5P 247091-27-6P**
247091-28-7P 247091-29-8P 247091-30-1P
247091-31-2P 247091-32-3P 247091-33-4P
247091-34-5P 247091-35-6P 247091-36-7P
247091-37-8P 247091-38-9P 247091-39-0P
247091-40-3P 247091-41-4P 247091-42-5P
247091-43-6P 247091-44-7P 247091-45-8P
247091-47-0P 247091-48-1P 247091-49-2P
247091-50-5P 247091-51-6P 247091-52-7P
247091-53-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of benzisoxazolyloctahydropyridopyrazine derivs.
as 5-HT1 receptor ligands)

RN 247091-25-4 CAPLUS
CN Benzenemethanamine, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-N-cyclopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-26-5 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)octahydro-7-[[3-[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenoxy]methyl]-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-27-6 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)-7-[[3-[(4-ethyl-1-piperazinyl)methyl]phenoxy]methyl]octahydro-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-28-7 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(5-fluoro-1,2-benzisoxazol-3-yl)octahydro-7-[[3-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-29-8 CAPLUS
CN 3-Azetidinol, 1-[[3-[[(7R,9aS)-2-(5-fluoro-1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-30-1 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(5-fluoro-1,2-benzisoxazol-3-yl)octahydro-7-[[3-(4-morpholinylmethyl)phenoxy]methyl]-, (7R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-31-2 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(4-fluoro-1,2-benzisoxazol-3-yl)octahydro-7-[[3-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-32-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)octahydro-7-[[3-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-33-4 CAPLUS
CN 3,4-Pyrrolidinediol, 1-[[3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]phenyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-34-5 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)octahydro-7-[[2-methyl-5-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-35-6 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)octahydro-7-[[3-methoxy-5-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-36-7 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)-7-[[4-chloro-3-(1-pyrrolidinylmethyl)phenoxy]methyl]octahydro-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-37-8 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)octahydro-7-[[4-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-38-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 7-[[3-(1-azetidinylmethyl)phenoxy]methyl]-2-(1,2-benzisoxazol-3-yl)octahydro-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-39-0 CAPLUS
CN Benzenemethanamine, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-40-3 CAPLUS
CN Benzenemethanamine, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-N-cyclohexyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-41-4 CAPLUS
CN 3-Pyrrolidinol, 1-[[3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]phenyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-42-5 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)-7-[[5-[[(2S,5S)-2,5-dimethyl-1-pyrrolidinyl]methyl]-2-methylphenoxy]methyl]octahydro-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-43-6 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)-7-[[5-[[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl]methyl]-2-methylphenoxy]methyl]octahydro-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-44-7 CAPLUS
CN 3-Pyrrolidinol, 1-[[3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]phenyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-45-8 CAPLUS
CN Benzenemethanamine, 3-[[(7S,9aS)-2-(1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-47-0 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)octahydro-7-[[2-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-48-1 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(1,2-benzisoxazol-3-yl)octahydro-7-[[4-(4-morpholinylmethyl)phenoxy]methyl]-, (7S,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-49-2 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(7-fluoro-1,2-benzisoxazol-3-yl)octahydro-7-[[3-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-50-5 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(6-fluoro-1,2-benzisoxazol-3-yl)octahydro-7-[[3-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-51-6 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(6,7-difluoro-1,2-benzisoxazol-3-yl)octahydro-7-[[3-(1-pyrrolidinylmethyl)phenoxy]methyl]-, (7R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-52-7 CAPLUS
CN 3-Azabicyclo[3.2.2]nonane, 3-[[3-[[(7R,9aS)-2-(5-fluoro-1,2-benzisoxazol-3-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247091-53-8 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine, 2-(5-fluoro-1,2-benzisoxazol-3-yl)octahydro-7-[[3-[(octahydro-2H-isoindol-2-yl)methyl]phenoxy]methyl]-, (7R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.35	180.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

STN INTERNATIONAL LOGOFF AT 10:09:02 ON 08 FEB 2006